StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the medical research company’s stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research note on Tuesday, February 25th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Trading Down 3.5 %

NASDAQ CTSO opened at $1.09 on Tuesday. The business has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.05. Cytosorbents has a one year low of $0.70 and a one year high of $1.61. The stock has a market capitalization of $59.60 million, a P/E ratio of -3.03 and a beta of 0.78. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds have recently added to or reduced their stakes in the company. Avenir Corp grew its stake in Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after acquiring an additional 118,387 shares during the period. Skylands Capital LLC lifted its holdings in shares of Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Cytosorbents in the fourth quarter valued at approximately $99,000. Finally, Northern Trust Corp lifted its holdings in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.